Wall Street analysts forecast that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will report $75.59 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Sucampo Pharmaceuticals’ earnings, with the highest sales estimate coming in at $77.70 million and the lowest estimate coming in at $73.00 million. Sucampo Pharmaceuticals posted sales of $73.02 million during the same quarter last year, which would indicate a positive year over year growth rate of 3.5%. The firm is expected to report its next quarterly earnings results on Wednesday, March 14th.

According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year sales of $75.59 million for the current year, with estimates ranging from $250.00 million to $255.10 million. For the next financial year, analysts expect that the firm will report sales of $261.10 million per share, with estimates ranging from $257.49 million to $263.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the previous year, the company earned $0.30 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year.

Several brokerages have recently commented on SCMP. UBS Group downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 target price on the stock. in a research note on Friday, January 5th. Mizuho restated a “neutral” rating and issued a $18.00 target price (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a research note on Wednesday, January 3rd. Leerink Swann restated a “market perform” rating and issued a $15.00 target price on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Maxim Group downgraded shares of Sucampo Pharmaceuticals to a “hold” rating in a research note on Monday, January 1st. Finally, ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 31st. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $21.58.

Shares of Sucampo Pharmaceuticals (SCMP) opened at $18.05 on Wednesday. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market cap of $841.80, a price-to-earnings ratio of -5.39, a PEG ratio of 5.07 and a beta of 1.45.

In related news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the transaction, the insider now owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.13% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of SCMP. Schwab Charles Investment Management Inc. lifted its position in Sucampo Pharmaceuticals by 36.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 246,796 shares of the biopharmaceutical company’s stock worth $2,592,000 after buying an additional 66,493 shares in the last quarter. Rhumbline Advisers lifted its position in Sucampo Pharmaceuticals by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 423 shares in the last quarter. SG Americas Securities LLC lifted its position in Sucampo Pharmaceuticals by 5.6% during the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 631 shares in the last quarter. Legal & General Group Plc lifted its position in Sucampo Pharmaceuticals by 9.0% during the 2nd quarter. Legal & General Group Plc now owns 44,756 shares of the biopharmaceutical company’s stock worth $470,000 after buying an additional 3,701 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in Sucampo Pharmaceuticals by 207.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 25,294 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 17,078 shares in the last quarter. Institutional investors and hedge funds own 64.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/17/75-59-million-in-sales-expected-for-sucampo-pharmaceuticals-inc-scmp-this-quarter.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.